文献速递甲状腺疾病

Afirma基因组测序分类器在年轻细胞学不确定甲状腺结节患者中的表现

Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该回顾性分析评估了Afirma基因组测序分类器(GSC)在49例小于21岁细胞学不确定甲状腺结节(ITN)患者中的性能。结果显示,GSC良性结果的阴性预测值为100%(95%CI 88-100),GSC可疑结果的恶性率为73.7%,灵敏度100%(95%CI 77-100),特异度86%(95%CI 70-95)。

要点

  • 年轻ITN患者中GSC良性结果阴性预测值达100%。
  • GSC可疑结果中73.7%为恶性,灵敏度100%。
  • GSC在年轻患者中表现良好,但样本量小需进一步验证。

核心结论

  • 在年轻ITN患者中,Afirma GSC在组织学或临床随访定义下表现出优异的阴性预测值。

研究设计与样本

  • 回顾性分析,纳入49例小于21岁患者的49个ITN,均有组织病理学或2年临床随访数据。

主要发现

  • 49个ITN中30个为GSC良性,19个为GSC可疑。
  • GSC可疑中14个(73.7%)为恶性,5个(26.3%)为良性。
  • 30个GSC良性病例均为组织学或临床良性。
  • 灵敏度100%(95%CI 77-100),特异度86%(95%CI 70-95),GSC良性阴性预测值100%(95%CI 88-100)。
  • 14例恶性肿瘤中9例为乳头状甲状腺癌,1例嗜酸细胞癌,1例NIFTP,3例滤泡状甲状腺癌。

关键数值与推荐

  • GSC良性结果的阴性预测值为100%(95%CI 88-100)。
  • GSC可疑结果的恶性率为73.7%,灵敏度100%(95%CI 77-100),特异度86%(95%CI 70-95)。

临床怎么用

  • 对于年轻ITN患者,Afirma GSC良性结果可高置信度排除恶性,支持保守管理。

局限性

  • 回顾性分析,样本量小(49例),需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The Afirma Genomic Sequencing Classifier (GSC) is validated in patients ≥ 21 years with a 96% negative predictive value for malignancy when GSC-(B)enign. Afirma GSC has not been formally studied in patients <21 years of age with indeterminate thyroid nodules (ITNs). OBJECTIVE: To evaluate Afirma GSC in young patients with ITNs. DESIGN: Retrospective analysis of Afirma GSC testing. SETTING: ITNs referred for molecular testing in a real-world setting. PARTICIPANTS: Forty-nine ITNs from 49 patients < 21 years of age who had histopathology or 2 years' clinical follow-up data ascertained. INTERVENTION: None. MAIN OUTCOME MEASURE: Afirma GSC test performance. RESULTS: In 49 ITNs from patients aged 9 to 20 years (median 18.5 [interquartile range, 17.3-19.8]), 30 were GSC-B and 19 GSC-(S)uspicious, among which 14 (73.7%) were malignant (ie, true positive) and 5 (26.3%) were benign (ie, false positive). All 30 Afirma GSC-B cases were either histologically (n = 9) or clinically benign (n = 21) (ie, true negative). All 14 malignancies were GSC-S (sensitivity 100% [95% CI, 77-100]); 30/35 clinically or histologically benign cases were GSC-B (specificity 86% [95% CI, 70-95]). Negative predictive value for an Afirma GSC-B result was 100% [95% CI, 88-100]. Genomic alterations were not detected in the 30 GSC-B samples. Among the 14 malignant samples, there were 9 papillary thyroid carcinomas, 1 oncocytic carcinoma, 1 noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and 3 follicular thyroid carcinomas. CONCLUSION: In young patients with ITNs, the Afirma GSC demonstrated an excellent negative predictive value when defining a thyroid nodule result by histology or clinical follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Castellanos LE, Bryan J, Ricarte-Filho JC, et al. Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2026. PMID: 41678360. doi:10.1210/clinem/dgag059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。